| human | Q5 |
| P1960 | Google Scholar author ID | NFr3YykAAAAJ |
| P213 | ISNI | 0000000137778535 |
| P2941 | Munk's Roll ID | richard-neil-fedorak |
| P496 | ORCID iD | 0000-0002-7382-0080 |
| P2038 | ResearchGate profile ID | Richard_Fedorak |
| P1153 | Scopus author ID | 7005513192 |
| P27 | country of citizenship | Canada | Q16 |
| P108 | employer | University of Alberta | Q640694 |
| P734 | family name | Fedorak | Q37436080 |
| Fedorak | Q37436080 | ||
| Fedorak | Q37436080 | ||
| P101 | field of work | gastroenterology | Q120569 |
| P735 | given name | Richard | Q1249148 |
| Richard | Q1249148 | ||
| Neil | Q5570878 | ||
| Neil | Q5570878 | ||
| P463 | member of | Royal Society of Canada | Q94301 |
| Royal College of Physicians of Edinburgh | Q2170997 | ||
| Canadian Academy of Health Sciences | Q5029644 | ||
| Royal College of Physicians, London | Q16003969 | ||
| P106 | occupation | physician | Q39631 |
| P21 | sex or gender | male | Q6581097 |
| Q36520699 | A 29-year-old woman with Crohn disease considering pregnancy |
| Q40069488 | A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials |
| Q52572938 | A defect in epithelial barrier integrity is not required for a systemic response to bacterial antigens or intestinal injury in T cell receptor-alpha gene-deficient mice. |
| Q39301057 | A machine-learned predictor of colonic polyps based on urinary metabolomics. |
| Q59120393 | A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study |
| Q35694889 | A randomized controlled trial of four precolonoscopy bowel cleansing regimens |
| Q56992312 | A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease |
| Q33916760 | A randomized trial of topical anesthesia comparing lidocaine versus lidocaine plus xylometazoline for unsedated transnasal upper gastrointestinal endoscopy |
| Q28270722 | A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease |
| Q59120756 | A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group |
| Q35100143 | A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels |
| Q59120887 | Acetic acid-induced colitis results in bystander ileal injury |
| Q59120396 | Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial |
| Q37240622 | Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. |
| Q34654409 | Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature |
| Q38184706 | Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis |
| Q46729988 | Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial |
| Q36881638 | American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. |
| Q53333615 | An imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens. |
| Q53196223 | Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. |
| Q52564350 | Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response. |
| Q59120486 | Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury |
| Q55050753 | Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice. |
| Q59120553 | Bones and Crohnʼs |
| Q34565768 | Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). |
| Q59120828 | Budesonide‐β‐D‐glucuronide: A Potential Prodrug for Treatment of Ulcerative Colitis |
| Q53517484 | CD4+CD25+ regulatory T cells have divergent effects on intestinal inflammation in IL-10 gene-deficient mice. |
| Q35962097 | Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact |
| Q34639486 | Canadian Digestive Health Foundation Public Impact Series 4: celiac disease in Canada. Incidence, prevalence, and direct and indirect economic impact |
| Q27023094 | Canadian Digestive Health Foundation Public Impact Series 5: Pancreatitis in Canada. Incidence, prevalence, and direct and indirect economic impact |
| Q34417015 | Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence, prevalence, and direct and indirect economic impact |
| Q24633952 | Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact |
| Q59120308 | Celiac Disease in Children With Inflammatory Bowel Disease: a Prospective Cohort Study |
| Q42659842 | Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab |
| Q36428382 | Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease |
| Q38045701 | Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease |
| Q34585762 | Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta |
| Q46196287 | Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial |
| Q46489074 | Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression |
| Q43512391 | Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply. |
| Q44769286 | Conservative approach to severe ulcerative colitis |
| Q36285782 | Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. |
| Q59120865 | Crypt cell production rate, enterocyte turnover time and appearance of transport along the jejunal villus of the rat |
| Q41867113 | Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps |
| Q36322290 | Development and validation of an administrative case definition for inflammatory bowel diseases |
| Q38672414 | Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey |
| Q33786052 | Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. |
| Q59120452 | Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent? |
| Q37516556 | Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns |
| Q30486789 | Distance management of inflammatory bowel disease: systematic review and meta-analysis |
| Q35216619 | Does the level of reproductive knowledge specific to inflammatory bowel disease predict childlessness among women with inflammatory bowel disease? |
| Q35056003 | Don't Forget the Doctor: Gastroenterologists' Preferences on the Development of mHealth Tools for Inflammatory Bowel Disease |
| Q35624602 | Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. |
| Q59120970 | Effect of misoprostol in preventing stress-induced intestinal fluid secretion in rats |
| Q37571701 | Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease |
| Q35995244 | Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples |
| Q52578345 | Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. |
| Q50482700 | Epithelial cell extrusion leads to breaches in the intestinal epithelium. |
| Q34511748 | Epithelial gaps in a rodent model of inflammatory bowel disease: a quantitative validation study |
| Q52507776 | FK506 increases permeability in rat intestine by inhibiting mitochondrial function. |
| Q42704205 | HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. |
| Q35452992 | Health care resource use and costs in Crohn's disease before and after infliximab therapy |
| Q53076589 | Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review for Development of a Core Outcome Set. |
| Q28296771 | Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial |
| Q44690253 | Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients |
| Q34511806 | Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease |
| Q33844058 | Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters |
| Q59120792 | Increased permeability occurs in rat ileum following induction of pancolitis |
| Q36082156 | Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study. |
| Q28246982 | Infliximab maintenance therapy for fistulizing Crohn's disease |
| Q88930148 | Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease |
| Q59120799 | Insulin downregulates diabetic-enhanced intestinal glucose transport rapidly in ileum and slowly in jejunum |
| Q59120768 | Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion |
| Q59120359 | Intravenous Injection of Endogenous Microbial Components Abrogates DSS-Induced Colitis |
| Q37992243 | Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis |
| Q35978793 | Is it time to re-classify Crohn's disease? |
| Q59120896 | Jejunum is preferable for construction of a bianchi bowel-lengthening procedure in swine short bowel |
| Q35670680 | Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. |
| Q59120602 | Lack of Interleukin-10 Leads to Intestinal Inflammation, Independent of the Time at Which Luminal Microbial Colonization Occurs |
| Q59120722 | Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease |
| Q59120727 | Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice |
| Q35655989 | Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. |
| Q35216610 | Living with inflammatory bowel disease: A Crohn's and Colitis Canada survey |
| Q59120870 | Low-Dose Cyclosporine for the Treatment of Crohn's Disease |
| Q26776151 | Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders |
| Q51753771 | Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. |
| Q36997228 | Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease |
| Q37797462 | Metabolomics and Detection of Colorectal Cancer in Humans: A Systematic Review |
| Q28646298 | Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria |
| Q59120846 | Methotrexate for the Treatment of Crohn's Disease |
| Q43531369 | Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease |
| Q33732599 | Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease. |
| Q59120921 | Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing |
| Q37175815 | Molecular patterns in human ulcerative colitis and correlation with response to infliximab |
| Q59120927 | Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats |
| Q42037558 | Murine ileocolic bowel resection with primary anastomosis. |
| Q46688826 | Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial |
| Q52598967 | Naturally occurring glycoalkaloids in potatoes aggravate intestinal inflammation in two mouse models of inflammatory bowel disease. |
| Q59120403 | Neonatal exposure to fecal antigens reduces intestinal inflammation |
| Q88376278 | Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study |
| Q59120632 | Normal Breast Milk Limits the Development of Colitis in IL-10–Deficient Mice |
| Q59120806 | Nutritional and intestinal effects of the novel immunosuppressive agents: Deoxyspergualin, rapamycin, and mycophenolate mofetil |
| Q59120493 | Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial |
| Q45975206 | Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. |
| Q41151384 | Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. |
| Q35026236 | Oropharyngeal Crohn's disease |
| Q36091362 | Patients undergoing colorectal cancer screening underestimate their cancer risk and delay presentation for screening |
| Q51620685 | Patients with Active Luminal Crohn's Disease Have Evidence of Significant Functional and Clinical Pulmonary Involvement. |
| Q34287642 | Patients with inflammatory bowel disease exhibit dysregulated responses to microbial DNA |
| Q51820079 | Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. |
| Q44409876 | Phenotypic features of Crohn's disease associated with failure of medical treatment. |
| Q46068220 | Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. |
| Q36207261 | Postoperative Crohn's disease. |
| Q35959598 | Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. |
| Q34789021 | Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field |
| Q33629237 | Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection |
| Q48677169 | Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study |
| Q36281405 | Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases |
| Q36036491 | Probiotics and prebiotics in gastrointestinal disorders. |
| Q35854517 | Probiotics and the management of inflammatory bowel disease. |
| Q36348570 | Probiotics in the management of inflammatory bowel disease. |
| Q24630676 | Probiotics in the management of ulcerative colitis |
| Q36457614 | Probiotics in the treatment of inflammatory bowel disease. |
| Q34796336 | Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study |
| Q46607949 | Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease |
| Q45259872 | Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease |
| Q45841458 | Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease |
| Q37342575 | Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. |
| Q51745588 | Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis. |
| Q34012172 | Recommendations for probiotic use--2008. |
| Q40128492 | Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis |
| Q38121115 | Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. |
| Q33792368 | Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. |
| Q57218404 | Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial |
| Q59120205 | Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohnʼs Disease |
| Q39538749 | Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study |
| Q53175432 | Small bowel fibrosis and systemic inflammatory response after ileocolonic anastomosis in IL-10 null mice. |
| Q59120814 | Small intestinal function following syngeneic transplantation in the rat. |
| Q45977890 | Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. |
| Q34524615 | Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation |
| Q88478503 | Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis |
| Q59120818 | TACROLIMUS (FK506)-ITS EFFECTS ON INTESTINAL GLUCOSE TRANSPORT1 |
| Q36085572 | TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. |
| Q35957791 | Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide |
| Q43904806 | The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting |
| Q33250647 | The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients |
| Q59120851 | The buried gastrostomy bumper syndrome: prevention and endoscopic approaches to removal |
| Q33997864 | The epidemiology of inflammatory bowel disease in Canada: a population-based study |
| Q51251490 | The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. |
| Q41454651 | The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection |
| Q59120962 | The physiology of adaptation to small bowel resection in the pig: An integrated study of morphological and functional changes |
| Q46805368 | The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease |
| Q36653913 | The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. |
| Q36220431 | The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. |
| Q59120386 | The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer |
| Q34842148 | Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin |
| Q46549276 | Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin |
| Q37800674 | Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology |
| Q40709112 | Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. |
| Q34833079 | Understanding why probiotic therapies can be effective in treating IBD. |
| Q46536231 | Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice |
| Q59120549 | VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis |
| Q50253608 | Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome |
| Q51589497 | Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. |
| Q34365574 | Vedolizumab as induction and maintenance therapy for Crohn's disease |
| Q59120480 | Vertebral Fractures and Role of Low Bone Mineral Density in Crohn’s Disease |
| Q26823927 | Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review |
| Q55056247 | World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. |
Search more.